Tanvex BioPharma, Inc. (TPE:6541)
35.95
+0.45 (1.27%)
Aug 19, 2026, 1:30 PM CST
Tanvex BioPharma Revenue
Tanvex BioPharma had revenue of 132.83M TWD in the quarter ending March 31, 2026, with 166.39% growth. This brings the company's revenue in the last twelve months to 483.94M, up 496.11% year-over-year. In the year 2025, Tanvex BioPharma had annual revenue of 400.97M with 1,056.27% growth.
Revenue (ttm)
483.94M
Revenue Growth
+496.11%
P/S Ratio
19.44
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.41B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.97M | 366.29M | 1,056.27% |
| Dec 31, 2024 | 34.68M | -26.73M | -43.53% |
| Dec 31, 2023 | 61.41M | 39.01M | 174.11% |
| Dec 31, 2022 | 22.40M | 17.00M | 314.43% |
| Dec 31, 2021 | 5.41M | 5.11M | 1,702.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Adimmune | 1.41B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| TCM Biotech International | 701.63M |
| TaiGen Biopharmaceuticals Holdings | 258.93M |
| Polaris Group | 69.27M |
| ACRO Biomedical | 52.76M |
| Gongwin Biopharm Holdings | 38.28M |